Jazz abandons sodium oxybate for fibromyalgia, and may drop intranasal clonazepam
This article was originally published in Scrip
Executive Summary
Jazz Pharmaceuticals revealed during the reporting of its first quarter results that it has abandoned its plan for seeking FDA approval of sodium oxybate, or JZP-6, as a treatment for fibromyalgia.